Endocrine therapies, e.g., the selective estrogen receptor modulator (SERM) Tamoxifen, block estrogen signaling in HR+ breast cancer cells, decreasing recurrence and improving survival [1]. The gene discussed is ESR1; the disease is breast carcinoma.